A Unique Case of Tacrolimus-Induced Dysphagia and Dysarthria in the Absence of Diagnostic Findings

Tacrolimus is a cornerstone immunosuppressant with high efficacy in preventing graft rejection in liver recipients. However, neurotoxic side effects such as posterior reversible encephalopathy syndrome (PRES) may occur. Patients often exhibit seizures, encephalopathy, headache, and hypertension. Thi...

Full description

Saved in:
Bibliographic Details
Published in:Transplant research and risk management 2022-01, Vol.14, p.47-51
Main Authors: Kanegi, Skyler L, Crane, George D, Scott, Kacie J, Thomas, Elizabeth
Format: Article
Language:English
Subjects:
Blood pressure
Consent
Cyclosporins
deceased
Delirium
Dysarthria
Dysphagia
Edema
Encephalopathy
Extubation
Glasgow Coma Scale
Graft rejection
Hospitals
Hypertension
Immunosuppressive agents
Intubation
Liver
Liver transplantation
Mortality
Neurotoxicity
pres
Seizures
Tacrolimus
Transplants & implants
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tacrolimus is a cornerstone immunosuppressant with high efficacy in preventing graft rejection in liver recipients. However, neurotoxic side effects such as posterior reversible encephalopathy syndrome (PRES) may occur. Patients often exhibit seizures, encephalopathy, headache, and hypertension. This case describes a 68-year-old female who received deceased donor liver transplantation and was started on an immunosuppressive regiment of tacrolimus which was adjusted to therapeutic trough. Graft function was preserved throughout post-operative course. The patient experienced a prolonged intubation period complicated by failed spontaneous breathing tests until post-operative day (POD) 8. From POD 8– 16, the patient experienced dysphagia. From POD 13– 16, the patient exhibited altered mental status and dysarthria. Throughout presentation of these symptoms, the patient had no radiographic findings, lab findings, or hypertension. On POD 15, tacrolimus was discontinued in favor of cyclosporine. By POD 17, the patient experienced complete resolution of her encephalopathy, dysphagia, and dysarthria. The patient was discharged on POD 24. This is the first known case of dysphagia and dysarthria as major presenting symptoms of tacrolimus toxicity. Discontinuing tacrolimus in favor of cyclosporine can successfully resolve a constellation of neurotoxic symptoms that do not fit a classic picture of PRES.
ISSN:1179-1616
1179-1616
DOI:10.2147/TRRM.S378778